Gift 5 articles to anyone you choose each month when you subscribe. Times are good at Eli Lilly. Wall Street’s insatiable appetite for weight-loss drug stocks looks set to turn the company into ...

Eli Lilly anticipates regulatory approval for its weight-loss drug Zepbound in Japan by mid-2025, boosting its global portfolio If Medicare were to start covering popular weight loss drugs such as ...

Eli Lilly and Company (NYSE: LLY) today announced a $4.5 billion investment to create the Lilly Medicine Foundry, a new center for advanced manufacturing and drug development. This unique facility ...

Eli Lilly has ben able to increase its manufacturing capacity to meet demand for its GLP-1 drugs. The company hopes this will reduce competition from drug compounding businesses. The stock looks ...

After hours: 11 October at 19:59 GMT-4 ...